Is Becton, Dickinson and Company (BDX) a Buy, Sell, or Hold?
NYSE : BDX
Becton, Dickinson and Company
$159.93 USD
$5.05 (3.26%)
- Volume
- 112.3K
- Average Volume
- 2.93M
- Market Capitalization
- $57.94B
- P/E Ratio
- 40.32
- Dividend Yield
- 2.35%
- Price Target
- $175.00
- Year High
- $187.35
- Year Low
- $127.59
- Day High
- —
- Day Low
- —
- Payout Ratio
- $1.04
- Current Ratio
- $0.94
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Thomas E. Polen Jr. |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Current Symbol | BDX |
| CUSIP | 075887109 |
| CIK | 0000010795 |
| Web | https://www.bd.com |
| Phone | 201 847 6800 |
| Currency | USD |
| Employees | 72000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.72 |
| Payout Ratio | 1.04 |
| Current Ratio | 0.94 |
| Quick Ratio | 0.55 |
| Cash Ratio | 0.10 |
Sales & Book Value
| Annual Sales | $21.84B |
| Price / Sales | 2.70 |
| Cash Flow | 11.20 |
| Price / Cash Flow | 18.36 |
| Price / Book | 1.85 |
Price Target and Rating
| Average Stock Price Forecast | $175.00 |
| High Stock Price Forecast | $204.00 |
| Low Stock Price Forecast | $159.00 |
| Forecast Upside/Downside | -8.61% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 34 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $5.83 |
| Trailing P/E Ratio | 40.32 |
| PEG Ratio | -1.63 |
| P/E Growth | -1.63 |
| Net Income | $1.68B |
| Net Margin | 5.33% |
| Pretax Margin | 8.14% |
| Return on Equity | 4.54% |
| Return on Assets | 2.24% |
Financials Score
| AltmanZ Score | 2.30 |
| Piotroski Score | 8.00 |
| Working Capital | -495M |
| Total Assets | 50.83B |
| Ebit | 2.3B |
| Market Cap | 56.11B |
| Total Liabilities | 26.7B |
Poll Results
About Becton, Dickinson and Company (NYSE:BDX) Stock
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including ... needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
BD to Announce Financial Results for its Third Quarter of Fiscal 2026
2026-07-09 16:15:00
FRANKLIN LAKES, N.J., July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
2026-07-08 13:10:22
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2026-07-07 17:30:00
Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.
5 Dividend Kings Long-Term Investors Should Own for the Next 20 Years
2026-07-07 14:00:00
Investors can count on these stocks about as much as any to continue their decades-long runs of excellence.
Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There
2026-07-01 11:32:19
Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks while retiring $2.1B in debt.
BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
2026-06-23 06:50:00
Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company.
5 Dividend Stocks to Buy and Hold Forever
2026-06-22 06:15:00
Get rich slowly. How? Hold these stocks and reinvest the dividends they pay.
3 Excellent Dividend Stocks to Buy on the Dip
2026-06-22 01:45:00
Despite facing some headwinds, these three companies still have strong long-term prospects. All three have raised their payouts for more than 50 consecutive years.
Frequently Asked Questions
-
What is the current Becton, Dickinson and Company (BDX) stock price?
-
Becton, Dickinson and Company(NYSE:BDX) stock price is $159.93 in the last trading session. During the trading session, BDX stock reached the peak price of $187.35 while $127.58648 was the lowest point it dropped to. The percentage change in BDX stock occurred in the recent session was 3.26% while the dollar amount for the price change in BDX stock was $5.05.
-
BDX's industry and sector of operation?
-
The NYSE listed BDX is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of BDX?
-
Meera Gopalakrishnan | Senior VP & Global Chief Marketing Officer
Carla Burigatto | Senior Vice President & Chief Communications Officer
Joseph Smith | Senior Vice President & Chief Scientific Officer
Vitor Roque | Executive Vice President & Chief Financial Officer
Denise Fleming | Executive Vice President & Chief Information Officer -
How many employees does BDX have?
-
Number of BDX employees currently stands at 72000. BDX operates from 1 Becton Drive, Franklin Lakes, NJ 07417-1880, US.
-
Link for BDX official website?
-
Official Website of BDX is: https://www.bd.com
-
How do I contact BDX?
-
BDX could be contacted at phone #201 847 6800 and can also be accessed through its website. BDX operates from 1 Becton Drive, Franklin Lakes, NJ 07417-1880, US.
-
How many shares of BDX are traded daily?
-
The average number of BDX shares traded daily for last 3 months was 2.93M.
-
What is the market cap of BDX currently?
-
The market value of BDX currently stands at $57.94B with its latest stock price at $159.93